scholarly journals Detection of Microbial Agents in Oropharyngeal and Nasopharyngeal Samples of SARS-CoV-2 Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Tyler Seckar ◽  
Xiang Lin ◽  
Dipayan Bose ◽  
Zhi Wei ◽  
Joseph Rohrbaugh ◽  
...  
Keyword(s):  
Diagnostic Techniques ◽  
Clinical Samples ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Respiratory Illnesses ◽  
Viral Genomes ◽  
Global Pandemic ◽  
Causative Agents ◽  
Novel Coronavirus ◽  
Microbial Agents

The novel coronavirus outbreak started in December 2019 and rapidly spread around the globe, leading to a global pandemic. Here we reported the association of microbial agents identified in oropharyngeal and nasopharyngeal samples from patients with SARS-CoV-2 infection, using a Pan-microarray based technology referred to as PathoChIP. To validate the efficiency of PathoChIP, reference viral genomes obtained from BEI resource and 25 SARS-CoV-2 positive clinical samples were tested. This technology successfully detected femtogram levels of SARS-CoV-2 viral RNA, which demonstrated greater sensitivity and specificity than conventional diagnostic techniques. Simultaneously, a broad range of other microorganisms, including other viruses, bacteria, fungi and parasites can be detected in those samples. We identified 7 viral, 12 bacterial and 6 fungal agents common across all clinical samples suggesting an associated microbial signature in individuals who are infected with SARS-CoV-2. This technology is robust and has a flexible detection methodology that can be employed to detect the presence of all human respiratory pathogens in different sample preparations with precision. It will be important for differentiating the causative agents of respiratory illnesses, including SARS-CoV-2.

scholarly journals Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

2020 ◽  
Author(s):  
Alessandra Oliva ◽  
Guido Siccardi ◽  
Ambra Migliarini ◽  
Francesca Cancelli ◽  
Martina Carnevalini ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Present Report ◽  
Case Series ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Global Pandemic ◽  
Large Teaching Hospital ◽  
Atypical Pathogens ◽  
Novel Coronavirus

Abstract The novel coronavirus SARS-CoV-2 has spread all over the world causing a global pandemic and representing a great medical challenge. Nowadays, there is limited knowledge on the rate of co-infections with other respiratory pathogens, with viral co-infection being the most representative agents. Co-infection with Mycoplasma pneumoniae has been described both in adults and pediatrics whereas only 2 cases of Chlamydia pneumoniae have been reported in a large US study so far. In the present report, we describe a series of 7 patients where co-infection with C. pneumoniae (n=5) or M. pneumoniae (n=2) and SARS-CoV-2 was detected in a large teaching hospital in Rome. An extensive review of the updated literature regarding the co-infection between SARS-CoV-2 and these atypical pathogens is also performed.

scholarly journals On the novel coronavirus (COVID-19): a global pandemic

2020 ◽  
Vol 9 (1) ◽  
pp. 103-114 ◽  
Author(s):  
James Louis-Jean ◽  
Magdonald Aime
Keyword(s):  
Relevant Information ◽  
Influenza Viruses ◽  
The Novel ◽  
Genetic Characteristics ◽  
Respiratory Illnesses ◽  
Global Issues ◽  
Global Pandemic ◽  
Animal Contact ◽  
Exposure Risks ◽  
Novel Coronavirus

Coronaviruses (COVS) are viruses transmitted through droplets of sputum from an infected person. Analyses identify COVS as zoonotic pathogens, possibly resulting from human-animal contact at animal markets. They share overlapping genetic characteristics with the avian influenza viruses from China. COVS released from humans through droplets of sputum and may land on various surfaces, which poses exposure risks; as studies have shown the virus can exist intact for a relatively long period of time (several days). The recent highly pathogenic COVS outbreak (COVID-19) emerged in Wuhan, China in 2019, include Severe Acute Respiratory Syndrome (SARS-COVS). This highly transmittable disease causes pneumonia and severe respiratory illnesses similar to SARS and MERS; it has a global mortality rate of about 6.13%. The virus has rapidly become a global pandemic, causing major global issues, including health, economic, and age-preference, among other issues. This text summarizes the nature of the emerging COVID-19 global pandemic while analyzing several factors concerning the etiology of the virus. This is done in an urgent effort to educate and provide relevant information about the virus.

scholarly journals Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

Infection ◽  
2020 ◽  
Vol 48 (6) ◽  
pp. 871-877 ◽  
Author(s):  
Alessandra Oliva ◽  
G. Siccardi ◽  
A. Migliarini ◽  
F. Cancelli ◽  
M. Carnevalini ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Present Report ◽  
Case Series ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Global Pandemic ◽  
Large Teaching Hospital ◽  
Atypical Pathogens ◽  
Novel Coronavirus

Abstract Introduction The novel coronavirus SARS-CoV-2 has spread all over the world causing a global pandemic and representing a great medical challenge. Nowadays, there is limited knowledge on the rate of co-infections with other respiratory pathogens, with viral co-infection being the most representative agents. Co-infection with Mycoplasma pneumoniae has been described both in adults and pediatrics whereas only two cases of Chlamydia pneumoniae have been reported in a large US study so far. Methods In the present report, we describe a series of seven patients where co-infection with C. pneumoniae (n = 5) or M. pneumoniae (n = 2) and SARS-CoV-2 was detected in a large teaching hospital in Rome. Results and conclusion An extensive review of the updated literature regarding the co-infection between SARS-CoV-2 and these atypical pathogens is also performed.

scholarly journals Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

2020 ◽  
Author(s):  
Alessandra Oliva ◽  
Guido Siccardi ◽  
Ambra Migliarini ◽  
Francesca Cancelli ◽  
Martina Carnevalini ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Present Report ◽  
Case Series ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Global Pandemic ◽  
Large Teaching Hospital ◽  
Atypical Pathogens ◽  
Novel Coronavirus

Abstract The novel coronavirus SARS-CoV-2 has spread all over the world causing a global pandemic and representing a great medical challenge. Nowadays, there is limited knowledge on the rate of co-infections with other respiratory pathogens, with viral co-infection being the most representative agents. Co-infection with Mycoplasma pneumoniae has been described both in adults and pediatrics whereas only 2 cases of Chlamydia pneumoniae have been reported in a large US study so far. In the present report, we describe a series of 7 patients where co-infection with C. pneumoniae (n=5) or M. pneumoniae (n=2) and SARS-CoV-2 was detected in a large teaching hospital in Rome. An extensive review of the updated literature regarding the co-infection between SARS-CoV-2 and these atypical pathogens is also performed.

scholarly journals Practices in Handling Clinical Samples in a COVID-19 Laboratory - An Experience from Chennai, India

2021 ◽  
Vol 10 (39) ◽  
pp. 3508-3510
Author(s):  
Saramma Mini Jacob ◽  
Kanagasabai Sivasangeetha ◽  
Durairaj Anitha ◽  
Singaram Kaplana
Keyword(s):  
Wide Spectrum ◽  
Clinical Manifestations ◽  
Gastrointestinal Symptoms ◽  
World Health ◽  
Clinical Samples ◽  
The Novel ◽  
Global Pandemic ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Respiratory Droplets

In early January 2020, China had started raising concerns of a new contagious disease caused by new strains of coronavirus, Severe Acute Respiratory SyndromeCoronavirus-2 (SARS-CoV-2). The World Health Organization (WHO) on March 11, 2020, had declared the novel coronavirus (COVID-19) outbreak a global pandemic. COVID-19 was transmitted from person to person through respiratory droplets generated when an infected person coughs, sneezes, breathing or through contact with a surface that has been contaminated 1 and through aerosols-airborne microdroplets.2 The clinical manifestations of COVID-19 represents a wide spectrum of disease ranging from mild to severe respiratory syndrome influenza-like illness with mainly lower respiratory tract symptoms, complicated by pneumonia and Acute Respiratory Distress Syndrome (ARDS), high fever, and headache. In many cases, loss of taste and smell and severe gastrointestinal symptoms were reported, as are cardiac problems, with the latter being perhaps secondary to a cytokine storm such as is seen in the more severely affected patients. 3 WHO COVID-19 dashboard on June 25th 2021 showed 179, 686, 071 confirmed cases worldwide.

scholarly journals Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

2020 ◽  
Author(s):  
Alessandra Oliva ◽  
Guido Siccardi ◽  
Ambra Migliarini ◽  
Francesca Cancelli ◽  
Martina Carnevalini ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Present Report ◽  
Case Series ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Global Pandemic ◽  
Large Teaching Hospital ◽  
Atypical Pathogens ◽  
Novel Coronavirus

Abstract The novel coronavirus SARS-CoV-2 has spread all over the world causing a global pandemic and representing a great medical challenge. Nowadays, there is limited knowledge on the rate of co-infections with other respiratory pathogens, with viral co-infection being the most representative agents. Co-infection with Mycoplasma pneumoniae has been described both in adults and pediatrics whereas only 2 cases of Chlamydia pneumoniae have been reported in a large US study so far. In the present report, we describe a series of 7 patients where co-infection with C. pneumoniae (n=5) or M. pneumoniae (n=2) and SARS-CoV-2 was detected in a large teaching hospital in Rome. An extensive review of the updated literature regarding the co-infection between SARS-CoV-2 and these atypical pathogens is also performed.

Synthetic and semi-synthetic drugs as promising therapeutic option for the treatment of COVID-19

2020 ◽  
Vol 20 ◽  
Author(s):  
Ekta Shirbhate ◽  
Preeti Patel ◽  
Vijay K Patel ◽  
Ravichandran Veerasamy ◽  
Prabodh C Sharma ◽  
...  
Keyword(s):  
Therapeutic Option ◽  
Antiviral Treatment ◽  
The Novel ◽  
Clinical Experiences ◽  
Synthetic Compounds ◽  
Synthetic Drugs ◽  
Global Pandemic ◽  
The World ◽  
Novel Coronavirus

: The novel coronavirus disease-19 (COVID-19), a global pandemic that emerged from Wuhan, China has today travelled all around the world, so far 216 countries or territories with 21,732,472 people infected and 770,866 deaths globally (as per WHO COVID-19 update dated August 18, 2020). Continuous efforts are being made to repurpose the existing drugs and develop vaccines for combating this infection. Despite, to date, no certified antiviral treatment or vaccine prevails. Although, few candidates have displayed their efficacy in in vitro studies and are being repurposed for COVID-19 treatment. This article summarizes synthetic and semi-synthetic compounds displaying potent activity in their clinical experiences or studies against COVID-19 and also focuses on mode of action of drugs being repositioned against COVID-19.

FEATURES OF THE COURSE AND TACTICS OF MANAGING CHILDREN WITH KIDNEYS AND URINARY TRACT DISEASES DURING THE PANDEMIC OF NEW CORONAVIRUS INFECTION COVID-19

2021 ◽  
Vol 100 (4) ◽  
pp. 74-79
Author(s):  
I.M. Kagantsov ◽  
◽  
V.V. Sizonov ◽  
V.G. Svarich ◽  
K.P. Piskunov ◽  
...  
Keyword(s):  
Age Groups ◽  
Clinical Manifestations ◽  
Routine Care ◽  
The Novel ◽  
Urinary System ◽  
Death Rates ◽  
Global Pandemic ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Significant Health

The novel coronavirus infection (SARS-CoV-2), which first appeared in Wuhan, China in December 2019, has been declared a global pandemic by WHO. COVID-19 affects people of all age groups. The disease in children is usually asymptomatic or mild compared to adults, and with a significantly lower death rates. Data on kidney damage in children with COVID-19, as well as the effect of coronavirus infection on the course of diseases of the genitourinary system, are limited, the risks of contracting a new coronavirus infection in children with significant health problems, including those with chronic kidney disease, remain uncertain. The pandemic has affected the activities of surgeons treating diseases of the urinary system in children. Since the prospects for the end of the pandemic are vague, it is necessary to formulate criteria for selecting patients who can and should be provided with routine care in the pandemic. The purpose of this review is to highlight the features of the clinical manifestations and treatment of children with COVID-19, occurring against the background of previous renal pathology or complicating its course.

scholarly journals Emergence of SARS-CoV-2 through recombination and strong purifying selection

2020 ◽  
Vol 6 (27) ◽  
pp. eabb9153 ◽  
Author(s):  
Xiaojun Li ◽  
Elena E. Giorgi ◽  
Manukumar Honnayakanahalli Marichannegowda ◽  
Brian Foley ◽  
Chuan Xiao ◽  
...  
Keyword(s):  
Host Species ◽  
Purifying Selection ◽  
New Drugs ◽  
Evolutionary Constraints ◽  
Binding Motif ◽  
The Novel ◽  
Global Pandemic ◽  
Show Evidence ◽  
Human Coronaviruses ◽  
Novel Coronavirus

COVID-19 has become a global pandemic caused by the novel coronavirus SARS-CoV-2. Understanding the origins of SARS-CoV-2 is critical for deterring future zoonosis, discovering new drugs, and developing a vaccine. We show evidence of strong purifying selection around the receptor binding motif (RBM) in the spike and other genes among bat, pangolin, and human coronaviruses, suggesting similar evolutionary constraints in different host species. We also demonstrate that SARS-CoV-2’s entire RBM was introduced through recombination with coronaviruses from pangolins, possibly a critical step in the evolution of SARS-CoV-2’s ability to infect humans. Similar purifying selection in different host species, together with frequent recombination among coronaviruses, suggests a common evolutionary mechanism that could lead to new emerging human coronaviruses.

scholarly journals Covid-19 and food security: Jeopardy management and posterity deliberations

2021 ◽  
Vol 10 (2) ◽  
pp. 01-05
Author(s):  
Augustine Owusu-Addo ◽  
Atianashie Miracle A ◽  
Chukwuma Chinaza Adaobi ◽  
Larissa Agbemelo-Tsomafo
Keyword(s):  
Food Processing ◽  
Respiratory Illness ◽  
The United States ◽  
The Novel ◽  
Food Handling ◽  
Global Pandemic ◽  
Food Borne ◽  
Novel Coronavirus ◽  
Food Borne Infections ◽  
Safety Guidelines

COVID-19, also known as the ‘novel coronavirus disease 2019’, is a respiratory illness and the causative pathogen is officially named as ‘SARS-CoV-2’. Infections with SARS-CoV-2 have now been amplified to a global pandemic – as of April 3, 2020, nearly 1,018,000 cases have been confirmed in more than 195 countries, including more than 300,000 cases within the United States. Public safety guidelines are followed worldwide to stop the spread of COVID-19 and stay healthy. Despite COVID-19 is a respiratory illness with mode of invasion through the respiratory tract, not the gastrointestinal tract, an average food consumer is anxious and concerned about the food safety. Could an individual catch the deadly contagious COVID-19 from groceries brought home from the supermarket – or from the next restaurant takeout order? This brief review elucidates the epidemiology and pathobiological mechanism(s) of SARS-CoV-2 and its implications in food-borne infections, transmission via food surfaces, food processing and food handling.

Sign in / Sign up

Export Citation Format

Share Document